What is the recommended treatment for osteoporosis in a 60-year-old woman?

Treatment Recommendation for Osteoporosis in a 60-Year-Old Woman

For a 60-year-old postmenopausal woman with osteoporosis at high fracture risk, initiate oral bisphosphonates (alendronate or risedronate weekly) or intravenous zoledronate as first-line pharmacologic therapy, combined with calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention strategies 1.

Risk Stratification First

Before initiating treatment, assess her fracture risk using a validated tool (FRAX or country-specific calculator) that incorporates:

• Bone mineral density (BMD) T-score from DXA scan
• Prior fragility fractures
• Age, body weight, family history
• Glucocorticoid use, smoking, alcohol intake
• Secondary causes of osteoporosis

This determines whether she is at high risk (standard osteoporosis) or very high risk (severe/multiple vertebral fractures), which dictates treatment selection 1, 2.

First-Line Pharmacologic Treatment

For High Fracture Risk (Standard Osteoporosis)

Bisphosphonates are the preferred initial therapy 1:

• Oral options: Alendronate 70 mg weekly or risedronate 35 mg weekly
• Intravenous option: Zoledronate 5 mg annually (particularly useful if adherence concerns or gastrointestinal intolerance)
• Alternative: Denosumab 60 mg subcutaneously every 6 months 1

The 2023 American College of Physicians guideline supports bisphosphonates for postmenopausal women with osteoporosis, showing reduction in hip and vertebral fractures without increased serious adverse events 3. The Endocrine Society 2019 guideline gives bisphosphonates a strong recommendation for high-risk postmenopausal women 1.

For Very High Fracture Risk

If she has severe or multiple vertebral fractures, consider anabolic therapy first:

• Teriparatide 20 mcg daily subcutaneous injection for up to 2 years, OR
• Abaloparatide 80 mcg daily subcutaneous injection for up to 2 years 1

Critical caveat: After completing anabolic therapy, you must transition to antiresorptive therapy (bisphosphonate or denosumab) to maintain bone density gains—the anabolic benefits disappear within 1 year without subsequent antiresorptive treatment 1.

Special Consideration for Age 60

At age 60, if she is within 10 years of menopause, has bothersome vasomotor symptoms, low cardiovascular risk, no history of breast cancer or VTE, and bisphosphonates/denosumab are not appropriate, hormone replacement therapy (HRT) can be considered as it prevents all fracture types 1. The 2024 UK guideline now recommends HRT as first-line in younger postmenopausal women with high fracture risk and low baseline risk for adverse events 4.

Essential Adjunctive Measures

All pharmacologic therapy must be accompanied by 1:

• Calcium: 1000-1200 mg daily (dietary plus supplement if needed)
• Vitamin D: 800-1000 IU daily (ensure 25-OH vitamin D level >30 ng/mL)
• Weight-bearing exercise: Walking, jogging, dancing 30+ minutes most days
• Resistance training: 2-3 times weekly to improve muscle strength
• Fall prevention: Home safety assessment, vision correction, medication review, balance training

Treatment Duration and Monitoring

Reassess fracture risk after 3-5 years of bisphosphonate therapy 1:

• High-risk patients: Continue therapy beyond 5 years
• Low-to-moderate risk patients: Consider a "bisphosphonate holiday" (temporary discontinuation up to 5 years)
• During holiday: Reassess every 2-4 years with DXA and clinical evaluation
• Reinitiate if BMD declines significantly, new fracture occurs, or risk factors change

Important distinction: Zoledronate requires reassessment at 3 years (not 5) due to its longer duration of action 1.

Denosumab-Specific Warning

Never stop denosumab abruptly—this causes rebound bone loss and multiple vertebral fractures in some patients 3, 1. If discontinuing denosumab, immediately transition to bisphosphonate therapy to prevent this complication.

Treatment Selection Algorithm

Choose bisphosphonates if:

• Standard high fracture risk without severe vertebral fractures
• Patient can tolerate oral medication and follow dosing instructions (upright 30 minutes, empty stomach)
• Cost is a consideration (bisphosphonates are least expensive)

Choose denosumab if:

• Bisphosphonate intolerance or contraindication (esophageal disorders, severe renal impairment)
• Adherence concerns with oral medications
• Patient can commit to strict 6-month injection schedule

Choose anabolic therapy (teriparatide/abaloparatide) if:

• Very high risk: severe or multiple vertebral fractures
• Failed bisphosphonate therapy (continued bone loss or new fractures on treatment)
• Patient can manage daily injections and afford higher cost

Common Pitfalls to Avoid

1. Don't use bisphosphonates indefinitely without reassessment—fracture risk changes over time 1
2. Don't stop denosumab without transition therapy—causes dangerous rebound 3, 1
3. Don't use anabolics without planning subsequent antiresorptive therapy—gains are lost 1
4. Don't forget dental precautions—assess dental health before bisphosphonates/denosumab; avoid invasive dental procedures during therapy due to rare osteonecrosis of jaw risk 5
5. Don't prescribe calcium/vitamin D alone as treatment—insufficient for established osteoporosis 1

Safety Profile

Bisphosphonates show no increased risk of serious adverse events, atrial fibrillation, or treatment withdrawal in trials up to 36 months 3. Long-term use (10 years) is safe in high-risk women 6. Rare complications include atypical femoral fractures and osteonecrosis of the jaw, but these risks are far outweighed by fracture prevention benefits in appropriate patients.